<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507065</url>
  </required_header>
  <id_info>
    <org_study_id>SLI381-314A</org_study_id>
    <nct_id>NCT00507065</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ADDERALL XR in the Treatment of Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase III, Randomized, Multicenter, Double-blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of ADDERALL XR With an Open Label Extension, in the Treatment of Adolescents Aged 13-17 With ADHD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and efficacy of ADDERALL XR compared to placebo in the treatment of
      adolescents (aged 13-17) with ADHD. Subjects were assigned to one of two cohorts based on
      weight (&lt;= 75 kg or &gt; 75 kg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to final visit of the double-blind phase of the study in the ADHD-RS-IV score in the cohort weighing less than or equal to 75 kg.</measure>
    <time_frame>approximately 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to final visit of double-blind phase of the study in ADHD-RS-IV score in the cohort weighing &gt;75 kg and the CGI for ADHD in both cohorts.</measure>
    <time_frame>Approximately 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events, labs, physical exam, ECG</measure>
    <time_frame>approximately 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">329</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Adderall XR (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall XR (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall XR (30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall XR (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mixed salts of a single-entity amphetamine (ADDERALL XR)</intervention_name>
    <arm_group_label>Adderall XR (10 mg)</arm_group_label>
    <arm_group_label>Adderall XR (20 mg)</arm_group_label>
    <arm_group_label>Adderall XR (30 mg)</arm_group_label>
    <arm_group_label>Adderall XR (40 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males/females 13-17 years of age meeting DSM-IV criteria for a primary diagnosis of
             ADHD

        Exclusion Criteria:

          -  Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with
             significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD

          -  Known non-responder to stimulant medication

          -  Documented allergy or intolerance to ADDERALL, ADDERALL XR or amphetamines

          -  Conduct Disorder, hypertension, history of seizure

          -  Tic disorder or Tourette's disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Pratt, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University - Child Study Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.adderallxr.com/</url>
    <description>FDA-approved labelling information, US only</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>FDA Recall information</description>
  </link>
  <results_reference>
    <citation>Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006 Feb;28(2):266-79.</citation>
    <PMID>16678648</PMID>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2007</study_first_submitted>
  <study_first_submitted_qc>July 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

